Potential application of neogalactosylalbumin in positron emission tomography evaluation of liver function

Figure 1 [¹⁸F]FNGA distribution in both control and fibrosis mice at various time points. Relative radioactivity levels are shown at various time points from organs of control mice (n = 21) (A) and CCl₄-induced fibrosis mice (n = 23) (B). ^bP < 0.01 vs Liver, ^aP < 0.05 vs Liver, ^eP < 0.001 vs Liver. [¹⁸F]FNGA: ¹⁸F-labeled neogalactosylalbumin.

Figure 2 Positron emission tomography images from a scanning of control mouse in a 30-min period. A: Each scan took 2 min followed by 1 min break; B: Dynamic radioactivity curves from region of interest for liver and heart from positron emission tomography scanning.

Figure 3 Comparison of the [¹⁸F]FNGA positron emission tomography scan parameters between fibrosis mice (n = 10) and control mice (n = 8). A: The LUA was significantly lower in fibrosis liver than that in normal liver; B: The T_p took significantly longer in fibrosis liver to reach a peak than in the normal liver; C: The LUR of fibrosis liver was significantly slower than that of the controls. ^aP < 0.05, ^bP < 0.01 vs fibrosis. [¹⁸F]FNGA: ¹⁸F-labeled neogalactosylalbumin; LUA: Liver uptake capacity; T_p: Peak time; LUR: Liver uptake rate.